News & Media

Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.


Media Contact:

Robert Murphy

Director, External Communications,
Otsuka America Pharmaceutical, Inc

Press Release

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) report that the U.S. Food and Drug Administration (FDA) has accepted a Supplemental New Drug Application (sNDA) for the treatment of schizophrenia in adolescents with Rexulti® (brexpiprazole) and has granted Otsuka and Lundbeck Priority Review. Up to one-third of patients with schizophrenia develop the disease during adolescence. Currently, Rexulti is approved in the U.S. for treatment of schizophrenia in adults and adjunctive treatment of major depressive disorder in adults.

US News

Sunovion Pharmaceuticals Inc. (Sunovion)its parent company Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo Dainippon Pharma) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today that the companies have entered into a worldwide license agreement for the joint development and commercialization of four compounds: ulotaront (SEP-363856), non-racemic ratio of amisulpride enantiomers (SEP-4199), SEP-378614 and SEP-380135.

Press Release

Sumitomo Dainippon Pharma Co., Ltd., its U.S.-based subsidiary Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Co., Ltd. announce today that we have executed a collaboration and license agreement for worldwide joint development and commercialization of the following four novel candidate compounds (hereinafter referred to as the "four compounds") currently under development in psychiatry and neurology area by Sumitomo Dainippon Pharma and Sunovion.

Press Release

The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today the launch of Otsuka’s Digital Pioneer Initiative (ODPI). The ODPI was created to accelerate Otsuka’s digital health capabilities through active and strategic engagement with early-stage companies focused on improving mental health and well-being.  MSRD also announced a strategic investment in Mindful Mamas—a digital solution for maternal and family mental wellness.